The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026.

AI data-labeling startup Handshake has acquired data label-auditing startup Cleanlab, the companies tell TechCrunch. Handshake began in 2013 as a platform for hiring college grads and launched a human ...

ACES Quality Management, a provider of enterprise quality management and control software for the financial services industry, announced on Tuesday its acquisition of data quality platform BaseCap ...

The deal adds a long-running dataset on tokenized real-world assets to RedStone’s oracle business as RWA activity spans public blockchains and institutional networks. Blockchain oracle provider ...

Software company ServiceNow could announce plans to acquire startup Armis as soon as this week in a potential $7 billion deal, Bloomberg reported. Armis, a cybersecurity firm, was last valued at $6.1 ...

ServiceNow Inc. is in advanced talks to buy the cybersecurity startup Armis in a deal that may be valued at as much as $7 billion and would represent the tech company’s largest acquisition to date. A ...

Some members of the maker community are distraught about Arduino’s new terms of service (ToS), saying that the added rules put the company’s open source DNA at ...

Among the changes that Defense Secretary Pete Hegseth laid out in his Nov. 7 address to industry is the idea that the Pentagon will be more willing to buy a system that provides “the 85% solution” now ...

Fintel reports that on November 21, 2025, HC Wainwright & Co. maintained coverage of Protalix BioTherapeutics (NYSEAM:PLX) with a Buy recommendation. As of November 17, 2025, the average one-year ...

Wright State University is poised to spend more than $2.2 million in legal expenses in its yearslong legal fight against its own former research funding arm, according to records obtained by the ...

Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $0.02914 EPS, expectations were $0.06. Operator: Greetings, and welcome to the Protalix BioTherapeutics, Inc. Third ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...